NOVA Medical, LLC, an emerging tissue repair and regenerative medicine company, announced its formation and a new collaborative approach to bringing innovative medical technologies to the U.S. healthcare market. Founded by experienced wound care leaders and guided by plastic and tissue repair surgeons, NOVA is building a commercialization platform grounded in transparency, integrity, and patient-centered decision-making. The company aims to connect promising technologies with real clinical needs while creating a more collaborative path to market.
"Most medical technology companies begin with a product and build a commercial strategy around it," said Dr. Christine Grogan, Co-Founder and Chief Executive Officer of NOVA Medical. "We're taking a different approach. We believe in returning to the fundamentals of responsible wound care—putting patients first, operating with integrity and embracing innovation where it truly makes a difference. We begin with the clinical need and build the right portfolio around it."
NOVA's portfolio strategy spans five interconnected stages of tissue repair: Prevent, Assess, Prepare, Restore, and Close. Its Plastic Surgeon Tissue Repair Surgeon Innovation Network will help identify unmet clinical needs, evaluate emerging technologies, guide product development, and inform portfolio selection. "As surgeons, we understand where clinical needs remain unmet," said Dr. Dan Kapp, Founding Member of NOVA's Plastic Surgeon Innovation Network. "NOVA gives us the opportunity to help shape innovation from the beginning and build a portfolio of complementary technologies around how we actually care for patients."
For clinicians, NOVA aims to provide access to thoughtfully selected, complementary technologies that support clinical decision-making throughout the tissue repair journey. For manufacturers, NOVA offers an alternative path to commercialization—combining clinical insight, experienced commercial leadership, and shared market access without requiring each company to build a national sales infrastructure independently. "The current wound care continuum demands a thoughtful and intentional approach to new ideas and technologies. Combining 150 years of plastic surgery expertise and 75 years of commercialization leadership, Nova Medical was created with that very idea in mind," said Dr. Mervin Low, Founding Member of NOVA's Plastic Surgeon Innovation Network.
What further distinguishes NOVA is its collaborative business model, designed to align the interests of manufacturers, surgeons, and the commercial organization. Participating manufacturers may have opportunities to share in the portfolio's broader financial success, creating incentives for collective success rather than competition among individual technologies. "We believe the next evolution in tissue repair won't come from any one product or company," said Chris Bauer, Co-Founder and Chief Commercial Officer. "It will come from bringing the right technologies, clinical expertise and commercial capabilities together. NOVA is being built to make that possible—and to create a model where everyone has a stake in making the entire portfolio successful."
Founded by Christine Grogan, DHA, MHA, MS, Chris Bauer, MBA, and Dawn Shepard, BSN, RN, NOVA brings together decades of experience in advanced wound care, medical devices, biologics, clinical practice, and commercialization. The founding team shares a wound care heritage that includes leadership experience at KCI and other established medical technology organizations. "Wound care doesn't need to become more complicated to become more effective," said Dawn Shepard, Co-Founder and Chief Clinical Officer. "Our focus is on getting back to the fundamentals while embracing innovations that address meaningful clinical needs and support responsible patient care."
NOVA's operating model combines NOVA Distribution, its primary commercial engine, with NOVA Consulting, which supports manufacturers preparing to enter the U.S. market. The company also intends to evaluate opportunities to develop or acquire technologies that complement its portfolio. Its broader vision is complemented by Women in Wound Care, an independently governed nonprofit focused on professional education and leadership development. More information is available at novamedical1.com and womeninwoundcare.org.
NOVA is advancing surgeon collaboration, manufacturer engagement, and organizational development in preparation for an anticipated 2027 commercial launch. The company's formation signals a potential shift in how medical technologies are commercialized, with a model that prioritizes clinical needs and shared success. For clinicians, this could mean access to a curated portfolio of complementary technologies; for manufacturers, a more efficient path to market; and for patients, potentially more effective tissue repair solutions.

